Searchable abstracts of presentations at key conferences in endocrinology

ea0081p403 | Pituitary and Neuroendocrinology | ECE2022

GH/IGF-I impact hepatic lipid accumulation in non-acromegalic individuals with and without non-alcoholic fatty liver disease

Fellinger Paul , Beiglboeck Hannes , Pfleger Lorenz , Smajis Sabina , Gajdosik Martin , Marculescu Rodrig , Vila Greisa , Winhofer Yvonne , Kautzky-Willer Alexandra , Krebs Michael , Krssak Martin , Wolf Peter

Background: Growth hormone (GH) plays an important role in modifying body composition. In acromegaly, a state of chronic GH/IGF-I excess, visceral and ectopic fat mass, especially in the liver, are significantly reduced. The aim of this study was to investigate the impact of GH/IGF-I on hepatocellular lipid content (HCL) and energy metabolism in a non-acromegalic cohort of patients with and without non-alcoholic fatty liver disease (NAFLD).Methods: We pe...

ea0063gp189 | Adrenal and Neuroendocrine - Clinical | ECE2019

Plasma renin concentration is associated with cardiac function and morphology in primary adrenal insufficiency

Wolf Peter , Beiglbock Hannes , Fellinger Paul , Pfleger Lorenz , Aschauer Stefan , Gessl Alois , Trattnig Siegfried , Kautzky-Willer Alexandra , Luger Anton , Winhofer Yvonne , Krssak Martin , Krebs Michael

Background: Despite adequate glucocorticoid (GC) and mineralocorticoid (MC) replacement therapy, primary adrenal insufficiency (AI) is associated with an increased mortality, mainly due to cardiovascular disease. The role of MC replacement is not known. Therefore we assessed whether renin concentrations during routine GC and MC substitution therapy are associated with cardiac function and morphology.Methods: 17 patients with AI underwent magnetic resonan...

ea0049ep638 | Growth hormone IGF axis - basic | ECE2017

GH is related to hepatic mitochondrial activity in humans

Wolf Peter , Smajis Sabina , Gajdosiik Martin , Pfleger Lorenz , Winhofer Yvonne , Anderwald Christian-Heinz , Trattnig Siegfried , Luger Anton , Krssak Martin , Krebs Michael

Background: Altered hepatic mitochondrial activity plays a key role in the development of non-alcoholic fatty liver disease (NAFLD). GH has been shown to stimulate mitochondrial function in skeletal muscle. Therefore we hypothesize that the time course of serum GH concentrations during an oral glucose tolerance test might be related to hepatic mitochondrial energy metabolism in vivo in humans.Methods: 15 volunteers (male/female: 7/8; 55±8 y...

ea0081p67 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Leptin increases VLDL triglyceride secretion and reduces hepatic lipid content in lean male subjects

Metz Matthaeus , Beghini Marianna , Pfleger Lorenz , Wolf Peter , Bastian Magdalena , Harreiter Jurgen , Baumgartner-Parzer Sabina , Marculescu Rodrig , Krebs Michael , Hackl Martina , Trauner Michael , Krssak Martin , Stangl Herbert , Kautzky-Willer Alexandra , Furnsinn Clemens , Scherer Thomas

Background: Leptin reduces hepatic lipid content in lipodystrophic and overweight, relatively hypoleptinemic NAFLD patients. However, the underlying mechanism is unknown. In rodents, the anti-steatotic action of leptin is mediated by an increase in VLDL secretion and depends on an intact vagal innervation of the liver.Methods: In this randomized, placebo-controlled, crossover trial, we study the effects of a single metreleptin injection (0.1 mg/kg body w...

ea0090ep744 | Pituitary and Neuroendocrinology | ECE2023

Growth hormone treatment tends to promote hepatic VLDL1-triglyceride export in humans

Baumgartner Clemens , Metz Matthaeus , Schnait Franziska , Tosin Anna , Beghini Marianna , Fellinger Paul , Beiglboeck Hannes , Pfleger Lorenz , Vila Greisa , Luger Anton , Kautzky-Willer Alexandra , Stangl Herbert , Krssak Martin , Furnsinn Clemens , Scherer Thomas , Krebs Michael , Wolf Peter

Introduction: Non-alcoholic fatty liver disease (NAFLD) is a systemic, metabolic condition associated with increased morbidity and mortality. Defined by an increase in hepatic lipid content (HCL), NAFLD develops in consequence of lipid oversupply and/or a diminished disposal of hepatic lipids. The latter may include an impaired export of triglycerides (TG) via the secretion of very-low density lipoprotein1 (VLDL1) particles, an important mechanism of the liver to protect itsel...

ea0099oc12.3 | Oral Communications 12: Diabetes, Obesity, Metabolism and Nutrition | Part II | ECE2024

Growth hormone promotes in-vivo hepatic triglyceride export in humans

Baumgartner Clemens , Metz Matthaeus , Pfleger Lorenz , Tosin Anna , Beghini Marianna , Beiglboeck Hannes , Fellinger Paul , Schnait Franziska , Vila Greisa , Luger Anton , Kautzky-Willer Alexandra , Freudenthaler Angelika , Baumgartner-Parzer Sabina , Stangl Herbert , Krssak Martin , Scherer Thomas , Krebs Michael , Wolf Peter

Overview: Non-alcoholic fatty liver disease (NAFLD) is defined as a chronic increase in intrahepatic lipids (IHL). A surplus of IHL can be compensated through increased lipid export via very-low density lipoprotein (VLDL) particles. Growth hormone (GH) is known to reduce visceral and ectopic fat. However, the main pathways responsible for the in-vivo decrease of IHL under the influence of GH are yet to be determined.Methods: We assessed hepatic lipid met...

ea0099rc5.7 | Rapid Communications 5: Pituitary and Neuroendocrinology | Part I | ECE2024

Changes of hepatic metabolism and lipidomic profile with biochemical improvement of acromegaly

Fellinger Paul , Pfleger Lorenz , Beiglboeck Hannes , Baumgartner Clemens , Marella Nara , Micko Alexander , Wolfsberger Stefan , Vila Greisa , Lmger Anton , Kautzky-Willer Alexandra , Krssak Martin , Scherer Thomas , Wolf Peter , Krebs Michael , Winhofer Yvonne

Overview: Despite marked insulin resistance, patients with active acromegaly have low hepatocellular lipid content (IHL) and an unfavourable hepatic lipid composition (UI). As previously shown, inadequate mitochondrial activity in the liver might counteract lipid accumulation in the liver. The purpose of this study was to understand changes in hepatic metabolism, and lipidomic profile with therapy of acromegaly.Methods: We prospectively included thirteen...

ea0081p352 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

The effects of an acute metreleptin injection on hepatic lipid metabolism in patients with lipodystrophy

Beghini Marianna , Metz Matthaeus , Wolf Peter , Bastian Magdalena , Hackl Martina , Baumgartner-Parzer Sabina , Kautzky-Willer Alexandra , Trauner Michael , Marculescu Rodrig , Krebs Michael , Harreiter Jurgen , Wabitsch Martin , von Schnurbein Julia , Brandt-Huenemann Stephanie , Stumvoll Michael , Miehle Konstanze , Santini Ferruccio , Ceccarini Giovanni , Magno Silvia , Pelosini Caterina , Krssak Martin , Pfleger Lorenz , Stangl Herbert , Furnsinn Clemens , Scherer Thomas

Objective: Treatment with metreleptin ameliorates hepatic steatosis in patients with lipodystrophy. The anti-steatotic effect of metreleptin is partially independent of its anorexic action, which suggests a direct effect of metreleptin on hepatic lipid metabolism. However, this mechanism is unknown. Based on previous findings in rodents, we hypothesized that metreleptin reduces hepatic lipid content by stimulating very-low density lipoprotein triglyceride (VLDL1-TG) secretion,...